[Special Stock] Dreamtech Develops COVID-19 Diagnostic Device in 30 Seconds with Israeli Investment Firm

[Asia Economy Reporter Hyunseok Yoo] Dreamtech is showing strong performance. The news that it has jointly developed a diagnostic device based on an 'electronic nose solution' with Israeli startup Nanoscent, which can determine COVID-19 infection status in 30 seconds, appears to have influenced its stock price.

As of 9:46 AM on the 4th, Dreamtech was trading at 8,220 KRW, up 23.61% (1,570 KRW) compared to the previous trading day.

Nanoscent developed the diagnostic sensor and algorithm, while Dreamtech modularized these to design the analysis device and developed and supplied a dedicated breath bag that can easily capture breath samples.

Dreamtech is engaged in smartphone components, fingerprint sensor module development, and automotive electronics business. Recently, it has been pursuing business diversification by promoting the healthcare sector as a new growth engine. It holds a 6.7% stake in Nanoscent.

Dreamtech and Nanoscent are preparing for mass production of the device aiming for European Conformity (CE) certification approval next month. The company expects that once the electronic nose solution receives official approval, it can be used as an initial screening system for many people in multi-use facilities such as airports, hospitals, and stores within a short time. Besides COVID-19, it can also be applied to acute respiratory syndromes such as MERS and SARS.

This content was produced with the assistance of AI translation services.